A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer

NCT07662720 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)

Interventions

DRUG: axelopran
DRUG: Pembolizumab

Sponsor

Glycyx Therapeutics

Collaborators

[object Object]
[object Object]
[object Object]